<DOC>
	<DOC>NCT02256514</DOC>
	<brief_summary>The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.</brief_summary>
	<brief_title>Open Label Trial of Immunotherapy for Advanced Liver Cancer</brief_title>
	<detailed_description>Hepcortespenlisimut-L (V5) immunotherapy of HCC in an open label setting with baseline alphafetoprotein serum levels and CT scan image as primary endpoints with monthly follow-up thereafter. Additional endpoints will include blood biochemistry indices and safety monitoring.</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Subjects who are at least 18 years old and are willing and capable of providing informed consent. Both men and nonpregnant women will be included. HCC diagnosis documented prior to Study Entry by either cytology/histology, CT scan, and AFP serum test higher or equal to 30 IU/ml. All subjects with reproductive potential are advised to utilize effective contraception throughout the course of this study. Health score status at baseline. Agreement to participate in the study and to give at least 3 samples of blood for lab tests. Readily available home or o other address where patient can be found. Subjects who might have already taken V5 in prior trials and have no baseline data. Those who met inclusion criteria can be retrospectively enrolled. Pregnant or breastfeeding women are excluded. Subjects who have taken other immunomodulatory therapies within 2 months prior to Entry: systemic corticosteroids, immune globulin (IV gamma globulin, IVIG), interferons, interleukins, pentoxifylline (Trental), thalidomide, filgrastim (GCSF), sargramostim (GMCSF); dinitrochlorobenzene (DNCB), thymosin alpha 1 (thymosin alpha), thymopentin, inosiplex (Isoprinosine), polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol), any locally available immune modulators, and any other therapeutic or preventive HCC vaccine. Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry. Evidence of active or acute cardiac disease, epilepsy, or lifethreatening diseases unrelated to HCC. Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>therapeutic vaccine</keyword>
</DOC>